GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Short-Term Debt

Zenith Capital (Zenith Capital) Short-Term Debt : $0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital Short-Term Debt?

Zenith Capital's Short-Term Debt for the quarter that ended in . 20 was $0.00 Mil.

Zenith Capital Short-Term Debt Historical Data

The historical data trend for Zenith Capital's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zenith Capital Short-Term Debt Chart

Zenith Capital Annual Data
Trend
Short-Term Debt

Zenith Capital Quarterly Data
Short-Term Debt

Zenith Capital Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Zenith Capital Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Zenith Capital's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zenith Capital (Zenith Capital) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corp (OTCPK:ZHCLF) » Definitions » Short-Term Debt
Comparable Companies
CBIO VINC AVTX UNCY TCRT ENTX SKYE PMCB HEPA ELEV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
300, 4820 RIchard Road SW, Calgary, AB, CAN, T3E 6L1
Website
Zenith Capital Corp is a biotechnology investment company. The company operates through its wholly-owned subsidiary Zenith Epigenetics Ltd. It is a clinical-stage biotechnology company focused on discovering and developing novel therapeutics. The company is developing various novel combinations of BET inhibitors with other targeted agents. Its lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC) in collaboration with Astellas and Newsoara and in metastatic triple-negative breast cancer.

Zenith Capital (Zenith Capital) Headlines

No Headlines